Sorrento Therapeutics Announces Entry Into Option Agreement to Exclusively License MPRO Inhibitors Against SARS-CoV-2 and Variants of Concern, Including Delta, From Texas A&M University

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement